
|Videos|September 26, 2017
Dr. Alberts Discusses Updates in Liver Cancer
Author(s)Steven R. Alberts, MD
Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses recent updates in liver cancer.
Advertisement
Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses recent updates in liver cancer.
Until the approval of regorafenib (Stivarga) in 2017, the only FDA-approved agent for the treatment of hepatocellular carcinoma (HCC) was sorafenib (Nexavar).
At the 2017 ASCO Annual Meeting, data on lenvatinib (Lenvima) were presented, showing comparable results to sorafenib and is likely to be approved for patients with HCC, says Alberts.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































